Modality
Cell Therapy
MOA
EGFRi
Target
WRN
Pathway
Neuroinflam
Endometrial Ca
Development Pipeline
Preclinical
~Jun 2018
→ ~Sep 2019
Phase 1
~Dec 2019
→ ~Mar 2021
Phase 2
~Jun 2021
→ ~Sep 2022
Phase 3
~Dec 2022
→ ~Mar 2024
NDA/BLA
Jun 2024
→ Feb 2031
NDA/BLACurrent
NCT07186769
683 pts·Endometrial Ca
2024-06→2031-02·Recruiting
683 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-02-074.9y awayPh3 Readout· Endometrial Ca
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2031-02-07 · 4.9y away
Endometrial Ca
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07186769 | NDA/BLA | Endometrial Ca | Recruiting | 683 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| 207-2754 | Samsung Biologics | Phase 1/2 | KRASG12D |